Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study

The effectiveness of COVID-19 vaccines wanes over time and the emergence of the SARS-CoV-2 Omicron variant led to the accelerated expansion of efforts for booster vaccination. However, the effect and contribution of booster vaccination with inactivated COVID-19 vaccines remain to be evaluated. We co...

Full description

Bibliographic Details
Published in:	Frontiers in Immunology
Main Authors:	Xiaofeng He, Biao Zeng, Ye Wang, Yulian Pang, Meng Zhang, Ting Hu, Yuanhao Liang, Min Kang, Shixing Tang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-10-01
Subjects:	COVID-19 inactivated vaccine vaccine effectiveness booster vaccination Omicron variant
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1257360/full

Similar Items

Inactivated COVID-19 vaccine booster dose shortened the viral shedding time of patients infected with the Omicron variant BA.2
by: Jun Wu, et al.
Published: (2023-06-01)

Immunity against Delta and Omicron variants elicited by homologous inactivated vaccine booster in kidney transplant recipients
by: Lei Zhang, et al.
Published: (2023-01-01)

COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects
by: Dorota Zarębska-Michaluk, et al.
Published: (2022-07-01)

The importance of booster vaccination in the context of Omicron wave
by: Zichun Wei, et al.
Published: (2022-09-01)

Omicron Booster in Ancestral Strain Vaccinated Mice Augments Protective Immunities Against Both Delta and Omicron Variants
by: Liqiu Jia, et al.
Published: (2022-07-01)

Vaccine Confidence and Uptake of the Omicron Bivalent Booster in Tennessee: Implications for Vulnerable Populations
by: Donald J. Alcendor, et al.
Published: (2023-04-01)

Vaccination with Omicron Inactivated Vaccine in Pre-vaccinated Mice Protects against SARS-CoV-2 Prototype and Omicron Variants
by: Yuntao Zhang, et al.
Published: (2022-07-01)

Transmission characteristics and inactivated vaccine effectiveness against transmission of the SARS-CoV-2 Omicron BA.2 variant in Shenzhen, China
by: Xiaofeng He, et al.
Published: (2024-01-01)

Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
by: Jianyang Liu, et al.
Published: (2023-12-01)

Effectiveness of Inactivated Coronavirus Disease 2019 Vaccine Against Omicron BA.2.2 Infection in Beijing, China, 2022: A Cohabitation Retrospective Cohort Study
by: Shuaibing Dong, et al.
Published: (2024-12-01)

Comparison of Safety of Different Vaccine Boosters Following Two-Dose Inactivated Vaccines: A Parallel Controlled Prospective Study
by: Zhi-Qiang Lin, et al.
Published: (2022-04-01)

Safety and Immunogenicity of a Booster Vaccination by CoronaVac or BNT162b2 in Previously Two-Dose Inactivated Virus Vaccinated Individuals with Negative Neutralizing Antibody
by: Kristi Tsz-Wan Lai, et al.
Published: (2022-04-01)

Inactivated mycobacterium paragordonae delivered via microneedle patches as a novel tuberculosis booster vaccine
by: Moonsu Lee, et al.
Published: (2025-12-01)

Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS‐CoV‐2 Omicron BA.1 variant
by: Zhongcheng Zhou, et al.
Published: (2022-06-01)

Protective Effect of Inactivated COVID-19 Vaccines against Omicron BA.2 Infection in Guangzhou: A Test-Negative Case-Control Real-World Study
by: Dingmei Zhang, et al.
Published: (2023-03-01)

mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines
by: Biyan Zhang, et al.
Published: (2022-06-01)

Boosting with Omicron-specific mRNA vaccine or historical SARS-CoV-2 vaccines elicits discriminating immune responses against Omicron variants
by: Yi Wu, et al.
Published: (2025-02-01)

Neutralization Effect of Sera against Delta and Omicron in Patients Recovering from COVID-19 and Inactivated Vaccine Recipients
by: Yajuan Zhu, et al.
Published: (2023-02-01)

Effectiveness of COVID-19 Vaccine Booster Shot Compared with Non-Booster: A Meta-Analysis
by: Yajuan Zhu, et al.
Published: (2022-08-01)

An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
by: Tao Li, et al.
Published: (2023-12-01)

Strategies and safety considerations of booster vaccination in COVID-19
by: Hanyan Meng, et al.
Published: (2022-06-01)

COVID-19 vaccine booster dose needed to achieve Omicron-specific neutralisation in nursing home residents
by: David H. Canaday, et al.
Published: (2022-06-01)

Inactivated vaccine effectiveness against symptomatic COVID-19 in Fujian, China during the Omicron BA.2 outbreak
by: Wenjing Ye, et al.
Published: (2023-12-01)

Selective adaptation of SARS-CoV-2 Omicron under booster vaccine pressure: a multicentre observational studyResearch in context
by: Ralf Duerr, et al.
Published: (2023-11-01)

COVID-19 Vaccine Booster Dose Fails to Enhance Antibody Response to Omicron Variant in Reinfected Healthcare Workers
by: Leire Fernández-Ciriza, et al.
Published: (2025-01-01)

The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis
by: Yuntao Zou, et al.
Published: (2022-07-01)

Modelling the potential public health impact of different vaccination strategies with an omicron-adapted bivalent vaccine in Thailand
by: Karan Thakkar, et al.
Published: (2023-12-01)

Efficacy of the COVID-19 vaccination in patients with asymptomatic or mild illness during the Omicron epidemic in Guangzhou: a multi-centre retrospective cohort study
by: Yuanda Xu, et al.
Published: (2024-12-01)

Is Booster Dose Strategy Sufficient for Omicron Variant of SARS-CoV-2?
by: Vivek P. Chavda, et al.
Published: (2022-02-01)

Short-Term Adverse Effects Following Booster Dose of Inactivated-Virus vs. Adenoviral-Vector COVID-19 Vaccines in Algeria: A Cross-Sectional Study of the General Population
by: Mohamed Lounis, et al.
Published: (2022-10-01)

The Effect of a Booster Dose mRNA Vaccine on COVID-19 Infection in Kidney Transplant Recipients after Inactivated or Viral Vector Vaccine Immunization
by: Sansanee Thotsiri, et al.
Published: (2022-10-01)

Real-world effectiveness of full and booster mRNA vaccination for coronavirus disease 2019 against disease severity during the delta- and omicron-dominant phases: A propensity score-matched cohort study using the nationwide registry data in Japan
by: Tetsuya Suzuki, et al.
Published: (2024-02-01)

Effect of second booster vaccination on clinical outcomes of Omicron-variant breakthrough infection: A propensity score matching cohort study
by: Denggao Peng, et al.
Published: (2024-01-01)

Risk factors for COVID-19 hospitalisation after booster vaccination during the Omicron period: A French nationwide cohort study
by: Agathe Turpin, et al.
Published: (2024-07-01)

Antibody response to SARS-CoV-2 WT and Omicron BA.4/5 of inactivated COVID-19 vaccine in patients with lung cancer after second and booster immunization
by: Chen Chen, et al.
Published: (2023-05-01)

Interactive effect of booster vaccination and vitamin D status on antibody production of Omicron variant‐infected adults: A real‐world cohort study
by: Denggao Peng, et al.
Published: (2023-10-01)

Immunogenicity and safety of different combinations involving a third booster dose of SARS-CoV-2 inactivated vaccine, inactivated quadrivalent influenza vaccine, and 23-valent pneumococcal polysaccharide vaccine in adults aged ≥60 years: a phase 4, randomized, open-label study
by: Shuang Bai, et al.
Published: (2024-08-01)

Protocol of an Exploratory Single-Arm Study to Evaluate the Safety and Immunogenicity of KD-414 as a Booster Vaccine for SARS-CoV-2 in Healthy Adults (KAPIVARA)
by: Yuriko Terayama, et al.
Published: (2022-06-01)

Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
by: Suvichada Assawakosri, et al.
Published: (2024-01-01)

Vaccination Is Associated With Shorter Time to Target Cycle Threshold Value in Patients With SARS-CoV-2 Omicron Variant
by: Jiajun Wu, et al.
Published: (2022-07-01)